NSHSF logo

NanoSphere Health Sciences Inc. (NSHSF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

NSHSF representa a NanoSphere Health Sciences Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 48/100

NanoSphere Health Sciences Inc. (NSHSF) Resumen de Asistencia Médica y Tuberías

CEOMichael Alexander Iverson
Sede CentralVancouver, CA
Año de la oferta pública inicial (OPI)2009
IndustriaBiotechnology

NanoSphere Health Sciences Inc. is a nano-biotechnology company providing biologically active compounds via its proprietary NanoSphere Delivery System. Targeting the cannabis, pharmaceutical, and animal health sectors in the US and Canada, the company aims to improve the bioavailability and effectiveness of supplements, nutraceuticals, and over-the-counter medications.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

NanoSphere Health Sciences Inc. presents a speculative investment opportunity within the nano-biotechnology sector. The company's NanoSphere Delivery System has potential in the cannabis, pharmaceutical, and animal health industries. A key value driver is the successful commercialization of the NanoSphere Delivery System through partnerships and licensing agreements. Growth catalysts include expanding applications of the technology into new therapeutic areas and securing regulatory approvals for pharmaceutical applications. The company's current P/E ratio is 0.36. However, investors may want to evaluate the risks associated with investing in OTC-listed companies, including limited liquidity and disclosure. As of 2026-03-17, the company's market capitalization is $0.00B, reflecting the early stage and speculative nature of the investment. The beta of 0.77 suggests lower volatility compared to the overall market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • NanoSphere Delivery System is the core technology, offering potential for enhanced bioavailability of active compounds.
  • Targets multiple sectors including cannabis, pharmaceutical, and animal health, diversifying application potential.
  • Headquartered in Vancouver, Canada, with operations in the United States and Canada.
  • P/E ratio of 0.36 indicates potential value, but requires further investigation due to limited financial data.
  • Beta of 0.77 suggests lower volatility compared to the overall market, which may appeal to risk-averse investors.

Competidores y Pares

Fortalezas

  • Proprietary NanoSphere Delivery System.
  • Potential for enhanced bioavailability.
  • Applications across multiple industries.
  • Experienced management team.

Debilidades

  • Limited financial resources.
  • Dependence on partnerships for commercialization.
  • Early stage of development.
  • OTC listing with limited liquidity.

Catalizadores

  • Upcoming: Potential partnerships with pharmaceutical companies to utilize the NanoSphere Delivery System.
  • Upcoming: Regulatory approvals for pharmaceutical applications of the NanoSphere technology.
  • Ongoing: Expansion of the NanoSphere Delivery System into new therapeutic areas.
  • Ongoing: Development of new product formulations utilizing the NanoSphere technology.
  • Ongoing: Geographic expansion into new markets, such as Europe and Asia.

Riesgos

  • Potential: Competition from established drug delivery companies.
  • Potential: Regulatory hurdles and compliance requirements.
  • Potential: Technological obsolescence of the NanoSphere Delivery System.
  • Ongoing: Limited financial resources and dependence on partnerships.
  • Ongoing: OTC listing with limited liquidity and transparency.

Oportunidades de crecimiento

  • Expansion into Pharmaceutical Applications: NanoSphere has the opportunity to extend its NanoSphere Delivery System into the pharmaceutical industry. This involves partnering with pharmaceutical companies to improve the delivery of existing drugs or developing new drug formulations utilizing the NanoSphere technology. The global pharmaceutical market is projected to reach $1.7 trillion by 2027, offering a substantial market for NanoSphere's delivery system. Success in this area hinges on clinical trials demonstrating improved efficacy and safety compared to traditional drug delivery methods. Timeline: Ongoing, with potential for significant revenue generation within 3-5 years pending regulatory approvals.
  • Penetration of the Animal Health Market: The animal health market presents another growth avenue for NanoSphere. Applying the NanoSphere Delivery System to animal health products, such as supplements and medications, can improve absorption and effectiveness. The global animal health market is expected to reach $75 billion by 2027. NanoSphere can target specific segments within this market, such as companion animals or livestock. Success depends on demonstrating the benefits of the NanoSphere technology to animal health companies and securing partnerships for product development and distribution. Timeline: Ongoing, with potential for revenue generation within 2-3 years.
  • Licensing Agreements and Partnerships: NanoSphere can generate revenue through licensing its NanoSphere Delivery System to other companies in the cannabis, pharmaceutical, and animal health industries. This involves granting companies the right to use the NanoSphere technology in their products in exchange for royalties or licensing fees. This approach allows NanoSphere to leverage its technology without the need for extensive manufacturing and distribution infrastructure. The success of this strategy depends on the attractiveness of the NanoSphere technology to potential licensees and the negotiation of favorable licensing terms. Timeline: Ongoing, with potential for immediate revenue generation upon signing licensing agreements.
  • Development of Proprietary Products: NanoSphere can develop and market its own line of products utilizing the NanoSphere Delivery System. This involves formulating supplements, nutraceuticals, or over-the-counter medications with the NanoSphere technology and selling them directly to consumers or through retail channels. This approach allows NanoSphere to capture a larger share of the value chain but requires significant investment in product development, manufacturing, and marketing. The success of this strategy depends on the ability to create innovative and differentiated products that appeal to consumers. Timeline: Ongoing, with potential for revenue generation within 1-2 years.
  • Geographic Expansion: NanoSphere currently operates primarily in the United States and Canada. Expanding into new geographic markets, such as Europe and Asia, presents a growth opportunity. This involves adapting the NanoSphere technology to meet the regulatory requirements of different countries and establishing partnerships with local distributors. The global market for drug delivery technologies is growing rapidly, particularly in emerging markets. Success depends on the ability to navigate regulatory complexities and establish a strong presence in new markets. Timeline: Ongoing, with potential for revenue generation within 3-5 years.

Oportunidades

  • Expansion into new therapeutic areas.
  • Securing regulatory approvals for pharmaceutical applications.
  • Penetration of the animal health market.
  • Geographic expansion into new markets.

Amenazas

  • Competition from established drug delivery companies.
  • Regulatory hurdles and compliance requirements.
  • Technological obsolescence.
  • Economic downturn affecting healthcare spending.

Ventajas competitivas

  • Proprietary NanoSphere Delivery System technology.
  • Potential for enhanced bioavailability compared to traditional delivery methods.
  • Applications across multiple industries (cannabis, pharmaceutical, animal health).
  • Partnerships and collaborations with established companies.

Acerca de NSHSF

NanoSphere Health Sciences Inc., incorporated in 2005 and headquartered in Vancouver, Canada, is a nano-biotechnology company focused on the delivery of biologically active compounds. The company's core technology is the NanoSphere Delivery System, a platform designed to enhance the bioavailability and effectiveness of various substances. This system utilizes nanotechnology to encapsulate and deliver supplements, nutraceuticals, and over-the-counter medications. NanoSphere's initial focus was on the cannabis industry, aiming to provide innovative delivery methods for cannabinoids. Over time, the company has expanded its scope to include the pharmaceutical and animal health industries, exploring applications of its delivery system for a broader range of therapeutic compounds. NanoSphere Health Sciences operates primarily in the United States and Canada, seeking partnerships and collaborations to commercialize its technology across different sectors. The company aims to differentiate itself through its proprietary delivery system, which it believes offers superior absorption and targeted delivery compared to traditional methods. NanoSphere continues to research and develop new applications for its technology, seeking to establish itself as a leader in nano-biotechnology delivery systems.

Qué hacen

  • Develops the NanoSphere Delivery System, a nanotechnology platform.
  • Enhances the bioavailability of active compounds.
  • Targets the cannabis industry with improved delivery methods for cannabinoids.
  • Expands applications to the pharmaceutical industry for drug delivery.
  • Applies the technology to the animal health industry for supplements and medications.
  • Seeks partnerships and collaborations for commercialization.
  • Operates in the United States and Canada.

Modelo de Negocio

  • Licensing the NanoSphere Delivery System to other companies.
  • Developing and marketing proprietary products utilizing the NanoSphere technology.
  • Partnering with companies in the cannabis, pharmaceutical, and animal health industries.
  • Generating revenue through royalties, licensing fees, and product sales.

Contexto de la Industria

NanoSphere Health Sciences Inc. operates within the biotechnology industry, specifically focusing on drug delivery systems. The market for drug delivery technologies is experiencing growth, driven by the need for more effective and targeted therapies. The competitive landscape includes companies developing novel delivery methods, such as nanoparticles, liposomes, and other advanced materials. NanoSphere aims to differentiate itself through its proprietary NanoSphere Delivery System. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and intense competition. NanoSphere's success depends on its ability to secure partnerships, obtain regulatory approvals, and demonstrate the superiority of its technology compared to existing delivery methods.

Clientes Clave

  • Cannabis companies seeking improved delivery methods for cannabinoids.
  • Pharmaceutical companies looking to enhance the bioavailability of drugs.
  • Animal health companies seeking to improve the effectiveness of supplements and medications.
  • Consumers purchasing products utilizing the NanoSphere Delivery System.
Confianza de la IA: 69% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de NanoSphere Health Sciences Inc. (NSHSF): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para NSHSF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para NSHSF.

MoonshotScore

48/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de NSHSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Michael Alexander Iverson

CEO

Michael Alexander Iverson serves as the Chief Executive Officer of NanoSphere Health Sciences Inc. His background includes experience in the healthcare and biotechnology sectors, with a focus on strategic leadership and business development. Iverson's expertise lies in guiding companies through growth phases, securing partnerships, and navigating the regulatory landscape. He has a track record of driving innovation and commercializing new technologies. His leadership is focused on expanding the applications of the NanoSphere Delivery System and building shareholder value.

Historial: Under Michael Alexander Iverson's leadership, NanoSphere Health Sciences Inc. has focused on expanding the applications of its NanoSphere Delivery System into new markets, including pharmaceuticals and animal health. He has overseen the development of new product formulations and the pursuit of strategic partnerships. A key achievement has been securing collaborations with companies in various sectors to commercialize the NanoSphere technology. His tenure has been marked by efforts to enhance the company's visibility and attract investment.

Información del mercado OTC de NSHSF

The OTC Other tier represents the lowest tier of the OTC market, indicating that NanoSphere Health Sciences Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing standards, leading to increased risks for investors. This tier often includes companies with limited operating history, distressed financials, or those that are thinly traded.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity in NSHSF shares is likely limited given its OTC Other listing. This typically translates to low trading volumes and wider bid-ask spreads, making it difficult to buy or sell shares quickly without significantly impacting the price. Investors may experience challenges in executing large orders, and the lack of liquidity can increase price volatility. The potential for price manipulation is also higher in thinly traded OTC stocks. Before investing, carefully assess the average daily trading volume and bid-ask spread to understand the liquidity risks.
Factores de riesgo OTC:
  • Limited liquidity due to OTC Other listing.
  • Lack of transparency and potential for incomplete financial disclosures.
  • Higher price volatility compared to exchange-listed stocks.
  • Potential for price manipulation due to thin trading volume.
  • Increased risk of fraud or mismanagement due to less stringent regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and audit reports.
  • Assess the management team's experience and track record.
  • Review the company's business plan and growth strategy.
  • Evaluate the competitive landscape and NanoSphere's market position.
  • Determine the company's compliance with regulatory requirements.
  • Understand the risks associated with the NanoSphere Delivery System technology.
  • Consult with a financial advisor before investing.
Señales de legitimidad:
  • Presence of a functioning website and contact information.
  • Patents or intellectual property protection for the NanoSphere Delivery System.
  • Partnerships or collaborations with established companies.
  • Experienced management team with relevant industry expertise.
  • Positive media coverage or industry recognition.

NSHSF Preguntas Frecuentes sobre Acciones de Healthcare

¿Cuáles son los factores clave para evaluar NSHSF?

NanoSphere Health Sciences Inc. (NSHSF) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Proprietary NanoSphere Delivery System.. Riesgo principal a monitorear: Potential: Competition from established drug delivery companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de NSHSF?

NSHSF actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de NSHSF?

Los precios de NSHSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre NSHSF?

La cobertura de analistas para NSHSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en NSHSF?

Las categorías de riesgo para NSHSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established drug delivery companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de NSHSF?

La relación P/E para NSHSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está NSHSF sobrevalorada o infravalorada?

Determinar si NanoSphere Health Sciences Inc. (NSHSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de NSHSF?

NanoSphere Health Sciences Inc. (NSHSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available due to OTC listing.
  • Financial data may not be readily accessible or audited.
  • Analyst coverage is limited.
Fuentes de datos

Popular Stocks